Evaluating MRI response criteria in microsatellite instability-high rectal cancer treated with immune checkpoint inhibitors
Authors:
Open Access
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Nonoperative Management of Mismatch Repair–Deficient TumorsNew England Journal of Medicine, 2025
- Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trialThe Lancet, 2025
- Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal CancerNew England Journal of Medicine, 2024
- MRI Tumor Regression Response to Neoadjuvant Chemotherapy Alone without Radiation for Rectal AdenocarcinomaRadiology, 2024
- 68Ga-FAPI PET imaging monitors response to combined TGF-βR inhibition and immunotherapy in metastatic colorectal cancerJournal of Clinical Investigation, 2023
- Watch-and-Wait Approach to Rectal Cancer: The Role of ImagingRadiology, 2023
- Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancerEuropean Journal of Cancer, 2021
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal CancerNew England Journal of Medicine, 2020
- Imaging of tumour response to immunotherapyEuropean Radiology Experimental, 2020
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeuticsThe Lancet Oncology, 2017